Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report)’s share price was down 5.4% during trading on Wednesday . The stock traded as low as C$6.86 and last traded at C$6.86. Approximately 1,750 shares were traded during trading, an increase of 141% from the average daily volume of 725 shares. The stock had previously closed at C$7.25.
Neuren Pharmaceuticals Trading Down 5.4 %
The company has a 50 day moving average price of C$8.13 and a 200 day moving average price of C$8.41.
About Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.
Read More
- Five stocks we like better than Neuren Pharmaceuticals
- Which Wall Street Analysts are the Most Accurate?
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Alphabet’s Officially In A Bear Market—Time To Buy?
- How Can Investors Benefit From After-Hours Trading
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
